FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2589164886> ?p ?o ?g. }

• W2589164886 endingPage "411" @default.
• W2589164886 startingPage "411" @default.
• W2589164886 abstract "411 Background: Many medical oncologists are still reluctant to use the standard sunitinib regimen in older patients (pts) with metastatic renal cell cancer (mRCC) because of concerns about tolerance. We assessed the routine use of first-line sunitinib in mRCC pts aged ≥70 yrs. Methods: We reviewed the clinical files of 154 pts aged ≥70 yrs with mRCC treated with first-line sunitinib in sixteen Italian Oncology Units from February 2006 to April 2011. Sunitinib 50 mg/d 4 wk on/2 wk off was considered the standard regimen (SR). All alternative schedules of sunitinib administration were considered as adapted regimens (AR). After univariate analysis a multivariate analysis was carried out by Cox regression model and included the following variables: age (<75 vs ≥75 yrs), Eastern Cooperative Oncology Group (ECOG) performance status (PS; 0-1 vs ≥2), presence of comorbidities (0 vs ≥1), lymphocytopenia (<1,000/microL vs >1,000/microL), prognostic score for VEGF-targeted agents according to Heng 2009 (good + intermediate prognosis vs poor prognosis), and treatment schedule (SR vs AR). Results: Median age was 74 yrs (range, 70-88 yrs). One hundred six pts (68.8%) received a SR and 48 (31.2%) received an AR consisting of 37.5 mg/d 4 wk on/2 wk off (32 cases, 67%), 25 mg/d 4 wk on/2 wk off (12 cases, 25%) and 37.5 mg continuous once-daily dosing in (4 cases, 8%). Pts treated with an AR were older than those treated with the SR (≥75 yrs, 56% vs 32%, respectively, p=0.008); with no differences for the other variables. Pts received a median of 4 sunitinib cycles with either SR or AR. Grade 3-4 toxicities occurred in 65% of SR and 42% of AR (p=0.008); dose reductions were required in 64% and 40%, respectively (p=0.005); discontinuations due to therapy-related adverse events occurred in 23% and 21%, respectively (p=0.967). Median progression-free survival (PFS) was 10.6 months (95% CI 8.7-15.3) and median overall survival (OS) was 20.1 months (95% CI 15.5-not reached). In multivariate analysis, only PS and the Heng score were predictors of either PFS or OS. Conclusions: Sunitinib is active and feasible in pts with mRCC aged ≥70 yrs. AR does not appear to influence PFS and OS and has a favorable impact on toxicity." @default.
• W2589164886 created "2017-03-03" @default.
• W2589164886 creator A5004001131 @default.
• W2589164886 creator A5006130493 @default.
• W2589164886 creator A5006430555 @default.
• W2589164886 creator A5020053836 @default.
• W2589164886 creator A5020324515 @default.
• W2589164886 creator A5022699386 @default.
• W2589164886 creator A5037725332 @default.
• W2589164886 creator A5059424755 @default.
• W2589164886 creator A5059919842 @default.
• W2589164886 creator A5071060598 @default.
• W2589164886 creator A5073892178 @default.
• W2589164886 creator A5074987624 @default.
• W2589164886 creator A5081355165 @default.
• W2589164886 creator A5082704939 @default.
• W2589164886 creator A5082776045 @default.
• W2589164886 creator A5086312742 @default.
• W2589164886 creator A5090736062 @default.
• W2589164886 date "2012-02-10" @default.
• W2589164886 modified "2023-09-27" @default.
• W2589164886 title "Sunitinib as first-line therapy in elderly patients (age 70 and older) with metastatic renal cell cancer." @default.
• W2589164886 doi "https://doi.org/10.1200/jco.2012.30.5_suppl.411" @default.
• W2589164886 hasPublicationYear "2012" @default.
• W2589164886 type Work @default.
• W2589164886 sameAs 2589164886 @default.
• W2589164886 citedByCount "1" @default.
• W2589164886 countsByYear W25891648862013 @default.
• W2589164886 crossrefType "journal-article" @default.
• W2589164886 hasAuthorship W2589164886A5004001131 @default.
• W2589164886 hasAuthorship W2589164886A5006130493 @default.
• W2589164886 hasAuthorship W2589164886A5006430555 @default.
• W2589164886 hasAuthorship W2589164886A5020053836 @default.
• W2589164886 hasAuthorship W2589164886A5020324515 @default.
• W2589164886 hasAuthorship W2589164886A5022699386 @default.
• W2589164886 hasAuthorship W2589164886A5037725332 @default.
• W2589164886 hasAuthorship W2589164886A5059424755 @default.
• W2589164886 hasAuthorship W2589164886A5059919842 @default.
• W2589164886 hasAuthorship W2589164886A5071060598 @default.
• W2589164886 hasAuthorship W2589164886A5073892178 @default.
• W2589164886 hasAuthorship W2589164886A5074987624 @default.
• W2589164886 hasAuthorship W2589164886A5081355165 @default.
• W2589164886 hasAuthorship W2589164886A5082704939 @default.
• W2589164886 hasAuthorship W2589164886A5082776045 @default.
• W2589164886 hasAuthorship W2589164886A5086312742 @default.
• W2589164886 hasAuthorship W2589164886A5090736062 @default.
• W2589164886 hasConcept C121608353 @default.
• W2589164886 hasConcept C126322002 @default.
• W2589164886 hasConcept C141071460 @default.
• W2589164886 hasConcept C144301174 @default.
• W2589164886 hasConcept C2777288759 @default.
• W2589164886 hasConcept C2777472916 @default.
• W2589164886 hasConcept C2779490328 @default.
• W2589164886 hasConcept C2781413609 @default.
• W2589164886 hasConcept C38180746 @default.
• W2589164886 hasConcept C71924100 @default.
• W2589164886 hasConcept C90924648 @default.
• W2589164886 hasConceptScore W2589164886C121608353 @default.
• W2589164886 hasConceptScore W2589164886C126322002 @default.
• W2589164886 hasConceptScore W2589164886C141071460 @default.
• W2589164886 hasConceptScore W2589164886C144301174 @default.
• W2589164886 hasConceptScore W2589164886C2777288759 @default.
• W2589164886 hasConceptScore W2589164886C2777472916 @default.
• W2589164886 hasConceptScore W2589164886C2779490328 @default.
• W2589164886 hasConceptScore W2589164886C2781413609 @default.
• W2589164886 hasConceptScore W2589164886C38180746 @default.
• W2589164886 hasConceptScore W2589164886C71924100 @default.
• W2589164886 hasConceptScore W2589164886C90924648 @default.
• W2589164886 hasIssue "5_suppl" @default.
• W2589164886 hasLocation W25891648861 @default.
• W2589164886 hasOpenAccess W2589164886 @default.
• W2589164886 hasPrimaryLocation W25891648861 @default.
• W2589164886 hasRelatedWork W1895933560 @default.
• W2589164886 hasRelatedWork W2056402925 @default.
• W2589164886 hasRelatedWork W2072245035 @default.
• W2589164886 hasRelatedWork W2096517981 @default.
• W2589164886 hasRelatedWork W2171237277 @default.
• W2589164886 hasRelatedWork W2322617799 @default.
• W2589164886 hasRelatedWork W2544140097 @default.
• W2589164886 hasRelatedWork W3151554875 @default.
• W2589164886 hasRelatedWork W4205243027 @default.
• W2589164886 hasRelatedWork W4205299447 @default.
• W2589164886 hasVolume "30" @default.
• W2589164886 isParatext "false" @default.
• W2589164886 isRetracted "false" @default.
• W2589164886 magId "2589164886" @default.
• W2589164886 workType "article" @default.